The short answer
Weekly mazdutide produced greater weight loss than placebo in a phase 3 trial in China. The findings describe this study population, not a head-to-head contest with other medicines.
Who took part?
The trial randomized 610 adults with overweight or obesity to mazdutide 4 mg, 6 mg, or placebo. Everyone received diet and activity guidance. Average starting weight was 87.2 kg.
Percent of starting weight
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Mazdutide 4 mg | −10.09% |
| Mazdutide 6 mg | −12.55% |
| Placebo | +0.45% |
What changed?
At the 32-week primary assessment, average weight change was:
−10.09% with mazdutide 4 mg.
−12.55% with mazdutide 6 mg.
+0.45% with placebo.
At week 48, changes were −11.00%, −14.01%, and +0.30%, respectively. These estimates included the effects of treatment stopping or starting other weight-loss therapies.
What were the trade-offs?
Digestive side effects were most common, usually mild or moderate. Adverse events led to stopping the trial regimen in 1.5%, 0.5%, and 1.0% of the three groups, respectively.
The useful takeaway
GLORY-1 adds evidence for a medicine targeting both GLP-1 and glucagon receptors. It does not establish superiority to semaglutide or tirzepatide, or predict one person’s response.
Sources
Ji and colleagues, NEJM, 2025. Funded by Innovent Biologics.